For the Inventor, By the Inventor

Enter assignee name

Mountain View, CA, United States of America

Chemocentryx, Inc.

USPTO Granted Patents = 219

% Expired Patents = 1.8

CIPO Patents = 8

EPO Patents = 69

Trademarks = 5

Forward Citations = 1,392

Loading Chart...

Loading Chart...

114 inventors (with patents filed for the assignee):

Penglie Zhang (109 out of 128 patents)

Sreenivas Punna (67 out of 67 patents)

Yibin Zeng (65 out of 69 patents)

4. Jay Patrick Powers (55 out of 126 patents)

5. Ju Yang (51 out of 55 patents)

6. Venkat Reddy Mali (50 out of 60 patents)

7. Rajinder Paul Singh (49 out of 378 patents)

8. Pingchen Fan (47 out of 63 patents)

9. Manmohan Reddy Leleti (41 out of 72 patents)

10. Christopher W Lange (41 out of 48 patents)

11. Hiroko Tanaka (41 out of 47 patents)

12. Thomas J Schall (41 out of 52 patents)

13. Viengkham Malathong (40 out of 52 patents)

14. Rebecca M Lui (39 out of 42 patents)

15. Antoni Krasinski (36 out of 37 patents)

Core Competencies:

CCR2 Antagonists

PD-L1 Inhibitors

C5aR Antagonists

CXCR2 Inhibitors

Immunomodulators

Triaryl Compounds

Inflammatory Bowel Disease

Focal Segmental Glomerulosclerosis

Combination Therapy

Heteroaryl Compounds

Tumor Treatment

Small Molecule Inhibitors

219 patents: Sort by Forward Citations

1. 12734166 - Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies (2026-09-15),

2. 12611409 - Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor (2026-04-28),

3. 12611404 - Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides (2026-04-28),

4. 12533354 - Triaryl compounds for treatment of PD-L1 diseases (2026-01-27),

5. 12497383 - Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases (2025-12-16),

6. 12350263 - Dosing and effect of C5a antagonist with ANCA-associated vasculitis (2025-07-08),

7. 12268675 - Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors (2025-04-08),

8. 12194032 - Method of treating focal segmental glomerulosclerosis (2025-01-14),

9. 12139475 - 2-oxindole compounds (2024-11-12),

10. 12054484 - Substituted tetrahydropyrans as CCR2 modulators (2024-08-06),

11. 12012403 - Aryl sulfonyl compounds as CCR6 inhibitors (2024-06-18),

12. 12011439 - Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors (2024-06-18),

13. 11986466 - Methods of treating solid tumors with CCR2 antagonists (2024-05-21),

14. 11951214 - Capsule formulations (2024-04-09),

15. 11945805 - Inhibitors of CXCR2 (2024-04-02),

ChemoCentryx is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer. They are dedicated to transforming the lives of patients through innovative science and targeted therapies. With a deep understanding of the immune system and its role in diseases, ChemoCentryx aims to provide breakthrough treatments that can make a meaningful difference in the lives of patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

219 Patents

#17 in Mountain View, CA

#411 in California

#1,911 in US

#3,898 in the World

Mountain View, CA, United States of America

Chemocentryx, Inc.

Forward Citations = 1,392

114 inventors:

Penglie Zhang (109 out of 128 patents)

Sreenivas Punna (67 out of 67 patents)

Yibin Zeng (65 out of 69 patents)

4. Jay Patrick Powers (55 out of 126 patents)

5. Ju Yang (51 out of 55 patents)

Please report any incorrect information to [email protected]

Loading…